Bausch and Lomb Newswire (Page 5)

Bausch and Lomb Newswire (Page 5)

Comprehensive Real-Time News Feed for Bausch and Lomb. (Page 5)

Results 81 - 100 of 749 in Bausch and Lomb

  1. Don't be confused. National Bank isn't investing in Lending ClubRead the original story

    Nov 7, 2016 | The Globe and Mail

    Deep breaths for National Bank of Canada investors. The news this morning that the bank is doing a $1.3-billion deal with troubled online-loan company Lending Club isn't what it seems.

    Comment?

  2. Seasoned Ophthalmology Executive Deb Jorn Joins pSivida to Focus on...Read the original story

    Nov 7, 2016 | Customer Interaction Solutions

    Ms. Jorn's primary responsibilities will be to establish collaborations leveraging pSivida's unique technologies and finalizing an EU partnership deal for the Company's Duraserta three-year uveitis, which was formerly known as Medidur. Ms. Jorn's experience and expertise in corporate licensing, M&A and alliance management helped her build US and global pharmaceutical businesses across numerous therapeutic areas, including ophthalmology.

    Comment?

  3. Valeant agrees to sell Paragon to settle U.S. antitrust chargesRead the original story w/Photo

    Nov 7, 2016 | Reuters

    Nov 7 Valeant Pharmaceuticals, which owns Bausch & Lomb, has agreed to sell Paragon Holdings to settle allegations that its acquisition of the company was illegal under antitrust law, the Federal Trade Commission said on Monday. The FTC said that Bausch & Lomb and Paragon together made more than 70 percent of three kinds of polymer discs used to make gas-permeable contact lenses.

    Comment?

  4. Earnings Outlook: Valeant earnings: Expect an update on plans to sell SalixRead the original story w/Photo

    Nov 7, 2016 | MarketWatch

    Valeant Pharmaceuticals International Inc. is scheduled to report third-quarter earnings before the bell Tuesday and analysts are expecting another decline in profit and revenue. has been battered over the past year, as a scandal about its drug pricing and accounting methods exploded into a major controversy that led to the ouster of longtime Chief Executive Michael Pearson and an overhaul of the company's operations and strategy.

    Comment?

  5. Wall Street just raised an eyebrow at ValeantRead the original story w/Photo

    Nov 2, 2016 | Silicon Alley Insider

    ... and board members have said that the company would not sell core assets. That basically includes Salix and Bausch and Lomb, which the company bought back in 2013. What this looks like, according to a lot of people on the Street, is desperation. If ...

    Comment?

  6. High-Quality Contact Lenses for Half the PriceRead the original story w/Photo

    Nov 2, 2016 | PRWeb

    ... Uber Early Architect and Founding CTO, Oscar Salazar; and Brian Levy, the former Chief Medical Officer of Bausch and Lomb. In mid-2015, Ben Cogan, now Co-founder and Co-CEO of Hubble, was down to his last few pairs of contact lenses. He realized he ...

    Comment?

  7. Valeant Stock Spikes on Reports of $10 Billion SaleRead the original story w/Photo

    Nov 1, 2016 | Fox News

    Valeant Pharmaceuticals International Inc. is in advanced talks to sell a big stomach-drug business to Japan's Takeda Pharmaceutical Co. for about $10 billion, a move that could ease pressure on Valeant over its hefty debt load.

    Comment?

  8. 3 Figures in Focus When Valeant Pharmaceuticals Intl. Inc. Reports Its Q3 ResultsRead the original story w/Photo

    Nov 1, 2016 | The Motley Fool

    Shares of the embattled drugmaker are down nearly 80% year to date, and dating back to last summer its shares have shed more than 90%, which translates to more than $80 billion in lost market value. Whether this trend continues or reverses in the near term could very well depend on how well Valeant performed during the third quarter.

    Comment?

  9. Hubble inks $7.2 mlnRead the original story

    Nov 1, 2016 | PE Hub

    ... Uber Early Architect and Founding CTO, Oscar Salazar; and Brian Levy, the former Chief Medical Officer of Bausch and Lomb. In mid-2015, Ben Cogan, now Co-founder and Co-CEO of Hubble, was down to his last few pairs of contact lenses. He realized he ...

    Comment?

  10. Advances in Enzymatic Analysis TechnologyRead the original story

    Nov 1, 2016 | Wines & Vines

    I last wrote about several laboratory analyses testing for important wine and grape constituents using enzymatic protocols measured spectroscopically in April 2014. Since that time, Megazyme introduced a new spectrophotometer called the MegaQuant Wave.

    Comment?

  11. pSivida Corp. Announces First Quarter Fiscal Year 2017 Financial...Read the original story

    Oct 31, 2016 | P&T Community

    The conference call may be accessed by dialing 312-7507 from the U.S. and Canada, or 813-4828 from international locations. The conference ID is 9987331.

    Comment?

  12. Optometry Market: Wide Usage of Contact Lenses and Glasses Due to...Read the original story w/Photo

    Oct 27, 2016 | SBWire

    ... f the top companies operating in optometry market are Johnson and Johnson Vision Care, Inc., Allergan, Inc., Bausch and Lomb, Inc., F. Hoffmann-La Roche Ltd., Carl Zeiss, Inc., Hoya Corp and others.

    Comment?

  13. Bill Miller: Valeant Can Double in ' YearsRead the original story

    Oct 26, 2016 | GuruFocus.com

    Bill Miller is an interesting value investor, as he is generally very outspoken. He made an appearance on CNBC and talked about Valeant .

    Comment?

  14. Global LASIK Treatment Market Research Report - Industry Analysis,...Read the original story w/Photo

    Oct 25, 2016 | PR Newswire

    The report extensively provides the market share, growth, trends and forecasts for the period 2015-2022. The market size in terms of revenue is calculated for the study period along with the details of the factors affecting the market growth .

    Comment?

  15. 3 candidates for worst CEO of 2016Read the original story w/Photo

    Oct 24, 2016 | USA Today

    A number of strong-performing companies have underperformed badly in 2016. Some have run into cyclical troubles.

    Comment?

  16. Ophthalmic Lasers Market worth 1,245.4 Million USD by 2021Read the original story

    Oct 19, 2016 | Emailwire.com

    This report studies the global ophthalmic lasers market for the forecast period of 2016 to 2021. This market is expected to reach USD 1,245.4 Million by 2021 from USD 970.2 Million in 2016, at a CAGR of 5.1% from 2016 to 2021.

    Comment?

  17. Frederick Meserall, Haddonfield opticianRead the original story w/Photo

    Oct 18, 2016 | Philly.com

    During World War II campaigns in North Africa and Italy, Frederick G. Meserall ran an Army Medical Corps mobile unit, one of the first staffed by opticians. Because it was often in combat zones, his unit provided eyeglasses to soldiers who, for instance, might have lost theirs while under fire.

    Comment?

  18. 3 Things Valeant Pharmaceuticals Needs to Do to Win Over Wall StreetRead the original story w/Photo

    Oct 17, 2016 | The Motley Fool

    Through Oct. 13, 2016, shares of the embattled pharmaceutical company have fallen 78%, and they're down more than 91% since peaking at an all-time high last summer. Yet in spite of Valeant's laundry list of woes, it remains quite profitable on an adjusted basis.

    Comment?

  19. Valeant offers lessons for all investorsRead the original story w/Photo

    Oct 17, 2016 | The Chronicle-Journal

    ... Valeant grew at a rapid pace using debt to purchase more than 100 companies. Two major deals for Salix and Bausch and Lomb cost Valeant a combined $23.2 billion. The company was a Wall Street darling whose share price reached its intraday apex in ...

    Comment?

  20. Stressed Out: Free Cash Flow Is All That Counts Now for ValeantRead the original story w/Photo

    Oct 14, 2016 | TheStreet.com

    With a $31 billion debt load, the drugmaker has to show it has the firepower needed to fend off creditors. Which drug businesses are they planning to put on the auction block? Will "crown jewel" Bausch & Lomb ever go up for sale? Will we see a recovery in Valeant's crucial dermatology businesses? Will a Hillary Clinton election win translate into a Big Pharma crackdown? With nearly $31 billion in debt on the books, the beleaguered Canadian drugmaker needs to start churning out cash to fend off creditors as maturities loom.

    Comment?